BR112016030686A2 - anticorpos anti tau humanizados - Google Patents
anticorpos anti tau humanizadosInfo
- Publication number
- BR112016030686A2 BR112016030686A2 BR112016030686A BR112016030686A BR112016030686A2 BR 112016030686 A2 BR112016030686 A2 BR 112016030686A2 BR 112016030686 A BR112016030686 A BR 112016030686A BR 112016030686 A BR112016030686 A BR 112016030686A BR 112016030686 A2 BR112016030686 A2 BR 112016030686A2
- Authority
- BR
- Brazil
- Prior art keywords
- tauopathy
- antibodies
- fragments
- chain variable
- variable region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Abstract
a presente invenção se refere a um anticorpo isolado ou fragmento de ligação a antígeno que se liga especificamente a tau, o anticorpo ou fragmento compreende uma região variável de cadeia pesada (vh) e uma região variável de cadeia leve (vl) tendo sequências de amino ácido determinadas aqui. também proporcionados são métodos de evitar ou tratar a tauopatia em um indivíduo, que compreende administrar a um ser humano em necessidade de terapia para a tauopatia com um ou mais anticorpos ou fragmentos como descrito aqui, em que os anticorpos ou fragmentos de ligação a antígeno são administrados sob condições e em uma quantidade eficaz para evitar ou tratar a tauopatia.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462018436P | 2014-06-27 | 2014-06-27 | |
US201462080903P | 2014-11-17 | 2014-11-17 | |
US201562170036P | 2015-06-02 | 2015-06-02 | |
PCT/US2015/038002 WO2015200806A2 (en) | 2014-06-27 | 2015-06-26 | Humanized anti-tau antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016030686A2 true BR112016030686A2 (pt) | 2017-10-31 |
Family
ID=54938957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016030686A BR112016030686A2 (pt) | 2014-06-27 | 2015-06-26 | anticorpos anti tau humanizados |
Country Status (27)
Country | Link |
---|---|
US (2) | US9957317B2 (pt) |
EP (1) | EP3182987B1 (pt) |
JP (3) | JP6626892B2 (pt) |
KR (1) | KR102431596B1 (pt) |
CN (1) | CN106659759B (pt) |
AU (2) | AU2015279643B2 (pt) |
BR (1) | BR112016030686A2 (pt) |
CA (2) | CA2953809C (pt) |
CL (1) | CL2016003346A1 (pt) |
CR (1) | CR20170026A (pt) |
DO (1) | DOP2016000335A (pt) |
EC (1) | ECSP17005649A (pt) |
ES (1) | ES2959528T3 (pt) |
IL (3) | IL249734B (pt) |
MA (1) | MA40229A (pt) |
MX (2) | MX2017000205A (pt) |
MY (1) | MY184540A (pt) |
NZ (1) | NZ727919A (pt) |
PE (1) | PE20170665A1 (pt) |
PH (2) | PH12016502608A1 (pt) |
RU (1) | RU2743152C2 (pt) |
SG (2) | SG10201914067XA (pt) |
TW (3) | TWI734975B (pt) |
UA (1) | UA122771C2 (pt) |
UY (1) | UY36194A (pt) |
WO (1) | WO2015200806A2 (pt) |
ZA (1) | ZA201608875B (pt) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2668159C2 (ru) | 2012-07-03 | 2018-09-26 | Вашингтон Юниверсити | Антитела против тау |
SG10201707855YA (en) | 2013-03-13 | 2017-10-30 | Prothena Biosciences Ltd | Tau immunotherapy |
TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
AR104875A1 (es) | 2015-06-05 | 2017-08-23 | Genentech Inc | Anticuerpos anti-tau y métodos de uso |
EP3307320A4 (en) * | 2015-06-12 | 2019-03-06 | C2N Diagnostics LLC | Stable formulations of humanized anti-tau antibodies |
KR102354845B1 (ko) | 2016-04-18 | 2022-01-24 | 파론 파머수티컬스 오와이 | 인간화 항 clever-1 항체 및 이의 용도 |
CN109415432B (zh) | 2016-05-02 | 2022-07-08 | 普罗塞纳生物科学有限公司 | Tau免疫疗法 |
CA3022765A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
PE20190261A1 (es) | 2016-05-02 | 2019-02-25 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
CA3030754C (en) * | 2016-07-20 | 2022-04-26 | Anahit Ghochikyan | Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
EP4269439A3 (en) * | 2016-09-10 | 2024-01-17 | Yeda Research and Development Co. Ltd | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
JP2019536471A (ja) | 2016-09-27 | 2019-12-19 | セロ・セラピューティクス・インコーポレイテッドCERO Therapeutics, Inc. | キメラエンガルフメント受容体分子 |
AR110321A1 (es) | 2016-12-07 | 2019-03-20 | Genentech Inc | Anticuerpos antitau y métodos de uso |
AU2017373884A1 (en) | 2016-12-07 | 2019-05-30 | Ac Immune Sa | Anti-tau antibodies and methods of their use |
MA47499A (fr) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc | Anticorps anti-tau et leurs procédés d'utilisation |
JP2018139530A (ja) * | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
EP3601337A1 (en) | 2017-03-28 | 2020-02-05 | Genentech, Inc. | Methods of treating neurodegenerative diseases |
BR112019022906A2 (pt) | 2017-05-02 | 2020-05-26 | Prothena Biosciences Limited | Anticorpos que reconhecem tau |
US11708423B2 (en) | 2017-09-26 | 2023-07-25 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules and methods of use |
SG11202002575UA (en) | 2017-10-02 | 2020-04-29 | Merck Sharp & Dohme | Chromane monobactam compounds for the treatment of bacterial infections |
JP6851549B2 (ja) | 2017-10-16 | 2021-03-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗タウ抗体及びその使用 |
CA3094934A1 (en) * | 2018-03-23 | 2019-09-26 | AbbVie Deutschland GmbH & Co. KG | Stable aqueous anti-tau antibody formulations |
US20210015865A1 (en) | 2018-03-28 | 2021-01-21 | Cero Therapeutics, Inc. | Chimeric engulfment receptors and uses thereof for neurodegenerative diseases |
CN113286819A (zh) * | 2018-08-01 | 2021-08-20 | 感应检查疗法公司 | 抗btn3a抗体及其在治疗癌症或感染性病症中的用途 |
CU20210073A7 (es) | 2019-03-03 | 2022-04-07 | Prothena Biosciences Ltd | Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs |
JP2022541539A (ja) * | 2019-07-15 | 2022-09-26 | アデル,インコーポレーテッド | 抗タウ抗体およびその使用 |
TWI780464B (zh) | 2019-08-06 | 2022-10-11 | 香港商新旭生技股份有限公司 | 結合至病理性tau種類之抗體及其用途 |
WO2021262791A1 (en) | 2020-06-25 | 2021-12-30 | Merck Sharp & Dohme Corp. | High affinity antibodies targeting tau phosphorylated at serine 413 |
WO2023028591A1 (en) | 2021-08-27 | 2023-03-02 | Genentech, Inc. | Methods of treating tau pathologies |
WO2023041805A1 (en) | 2021-09-20 | 2023-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
WO2023178049A1 (en) | 2022-03-14 | 2023-09-21 | Genentech, Inc. | Predicting neurodegenerative diseases based on speech analyses |
WO2023250326A1 (en) | 2022-06-21 | 2023-12-28 | Genentech, Inc. | Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses |
CN115724970B (zh) * | 2022-07-27 | 2023-10-20 | 生工生物工程(上海)股份有限公司 | 一种特异性结合e-cad多肽的结合蛋白及其应用 |
CN116375857A (zh) * | 2023-03-30 | 2023-07-04 | 天津鸿宇泰生物科技有限公司 | 一种用于检测Tau蛋白的单链抗体及其制备方法和应用 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI884505A (fi) | 1987-10-02 | 1989-04-03 | Du Pont | Immunoanalys, i vilken anvaends igg-uppsnappande antikroppar och detekteringssystem foer flera monoklonala antikroppar. |
WO1993003369A1 (en) | 1991-08-01 | 1993-02-18 | Voorheis Paul H | Diagnostic method for alzheimer's disease |
US5733734A (en) | 1991-08-14 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments |
AU662178B2 (en) | 1991-10-25 | 1995-08-24 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US6200768B1 (en) | 1991-12-06 | 2001-03-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Method of screening for compounds that dissolve paired helical filaments |
US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
JPH06239899A (ja) | 1993-02-12 | 1994-08-30 | Teijin Ltd | ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法 |
AU710952B2 (en) | 1994-07-29 | 1999-09-30 | Innogenetics N.V. | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
WO1997034145A1 (fr) | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant |
AU5508798A (en) | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
US6797478B1 (en) | 1998-03-05 | 2004-09-28 | University Of Cincinnati | Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies |
JP4624559B2 (ja) | 1998-09-08 | 2011-02-02 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 初期cnsダメージのマーカーとしてのタウ |
US6972125B2 (en) * | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
US6589746B1 (en) | 1999-10-21 | 2003-07-08 | University Of Cincinnati | Method of detecting axonally-derived protein tau in patients with traumatic CNS injury |
JP4582874B2 (ja) | 2000-07-13 | 2010-11-17 | 富士通株式会社 | 偏波モード分散補償方法および偏波モード分散補償装置 |
AT500379B8 (de) * | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
AR035119A1 (es) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
AU2002362197A1 (en) | 2001-12-28 | 2003-07-24 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
ES2916174T3 (es) | 2002-05-02 | 2022-06-28 | Wyeth Holdings Llc | Conjugados de transportador derivado de caliqueamicina |
ATE391781T1 (de) | 2002-07-12 | 2008-04-15 | Axon Neuroscience | Transgenes tier welches das trunkierte alzheimer tau protein exprimiert |
EP1535930B1 (en) | 2002-08-14 | 2010-10-06 | Mitsubishi Chemical Medience Corporation | Antibody specific to central nervous system tau protein |
FI20030652A0 (fi) | 2003-04-30 | 2003-04-30 | Susann Eriksson | Parannettu immunomääritys |
CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
EP1716233B1 (en) * | 2004-01-30 | 2009-08-26 | Maxygen Holdings Ltd. | Regulated stop codon readthrough |
US7238788B2 (en) | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
KR20100036324A (ko) | 2005-02-19 | 2010-04-07 | 주식회사 피플바이오 | 멀티머-형성 폴리펩타이드의 모노머로부터 멀티머를 분별 검출하는 방법 |
US20070134724A1 (en) | 2005-08-04 | 2007-06-14 | Peter Davies | Phosphorylation of tau by abl |
ES2321996B1 (es) | 2006-01-26 | 2010-03-05 | Consejo Superior Investig. Cientificas | Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias. |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
ZA200900545B (en) * | 2006-07-18 | 2010-03-31 | Sanofi Aventis | Antagonist antibody against EPHA2 for the treatment of cancer |
WO2008140639A2 (en) | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
DK2276485T3 (da) | 2008-04-24 | 2014-10-13 | Bristol Myers Squibb Co | Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom |
CN101307108B (zh) | 2008-06-25 | 2012-04-04 | 南京川博生物技术有限公司 | 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途 |
AU2009296392B2 (en) * | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
WO2010096751A1 (en) | 2009-02-23 | 2010-08-26 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta |
US9605054B2 (en) | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
WO2010129674A2 (en) | 2009-05-05 | 2010-11-11 | New York University | Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins |
US8748386B2 (en) | 2009-06-10 | 2014-06-10 | New York University | Immunological targeting of pathological Tau proteins |
US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
CN102144341B (zh) | 2009-06-17 | 2013-02-27 | 株式会社藤仓 | 多包层光纤、光纤模块、光纤激光器及光纤放大器 |
CA2768346A1 (en) | 2009-07-30 | 2011-02-03 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
EP2470211B1 (en) | 2009-08-28 | 2016-01-27 | The Board of Regents of The University of Texas System | Antibodies that bind tau oligomers |
CN102549438B (zh) | 2009-09-24 | 2014-10-29 | 国家健康与医学研究院 | Fkbp52-tau相互作用作为新颖治疗靶点用于治疗涉及tau机能失调的神经障碍 |
US20130095492A1 (en) | 2010-03-05 | 2013-04-18 | Albert Einstein College Of Medicine Of Yeshiva University | Method of detecting tau protein and tau fragments in serum |
CA2795279C (en) * | 2010-04-08 | 2020-05-05 | Jn Biosciences Llc | Antibodies to cd122 |
AU2013205313B2 (en) | 2010-10-07 | 2016-05-19 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
TW201216985A (en) | 2010-10-07 | 2012-05-01 | Ac Immune Sa | Pharmaceutical composition |
US20130295021A1 (en) | 2010-10-11 | 2013-11-07 | Feng Chen | Human anti-tau antibodies |
US20120244174A1 (en) | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
US8697076B2 (en) | 2011-04-27 | 2014-04-15 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
US20120321594A1 (en) | 2011-05-06 | 2012-12-20 | New York University | Methods of controlling axon or dendrite development of neuronal cells |
WO2012162179A1 (en) | 2011-05-20 | 2012-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
GB201111361D0 (en) | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
WO2013012811A2 (en) | 2011-07-19 | 2013-01-24 | New York University | Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
CN104185640B (zh) | 2011-09-19 | 2018-07-20 | 阿克松神经***科学公司 | 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断 |
CN104080806B (zh) | 2011-10-07 | 2018-01-19 | Ac免疫有限公司 | 识别Tau的磷酸化特异抗体 |
WO2013063086A1 (en) | 2011-10-24 | 2013-05-02 | Intellect Neurosciences, Inc. | Compositions and methods for treatment of proteinopathies |
CA2853719A1 (en) * | 2011-10-27 | 2013-05-02 | Nkt Therapeutics Inc. | Humanized antibodies to inkt |
HUE045656T2 (hu) | 2011-12-20 | 2020-01-28 | Janssen Biotech Inc | PHF-tau elleni ellenanyagok és alkalmazásuk |
US20130251731A1 (en) * | 2012-03-22 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies |
KR102132041B1 (ko) | 2012-04-05 | 2020-07-09 | 에이씨 이뮨 에스.에이. | 인간화된 타우 항체 |
WO2013177104A2 (en) | 2012-05-21 | 2013-11-28 | Felder Mitchell S | Treatment for tauopathies |
SG11201407878VA (en) | 2012-05-31 | 2015-01-29 | Univ Osaka City | Therapeutic agent or prophylactic agent for dementia |
RU2668159C2 (ru) | 2012-07-03 | 2018-09-26 | Вашингтон Юниверсити | Антитела против тау |
PE20150646A1 (es) * | 2012-08-16 | 2015-05-21 | Ipierian Inc | Metodos de tratamiento de una tauopatia |
US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
JP2015527369A (ja) | 2012-08-21 | 2015-09-17 | インスティテュート フォー モレキュラー メディシン, インコーポレイテッド | アミロイド、タウおよびα−シヌクレインの沈着に関連する疾患に関する組成物および方法 |
EP4356927A2 (en) | 2012-10-12 | 2024-04-24 | Arizona Board of Regents on behalf of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
US9910048B2 (en) | 2012-12-03 | 2018-03-06 | Washington University | Method for detection of aggregates in biological samples |
US8921150B2 (en) | 2012-12-06 | 2014-12-30 | Taiwan Semiconductor Manufacturing Co., Ltd. | Process to achieve contact protrusion for single damascene via |
US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
WO2014096321A1 (en) | 2012-12-21 | 2014-06-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies |
MX2015008024A (es) | 2012-12-21 | 2016-08-08 | Biogen Int Neuroscience Gmbh | Anticuerpos anti-tau humanos. |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
SG10201707855YA (en) | 2013-03-13 | 2017-10-30 | Prothena Biosciences Ltd | Tau immunotherapy |
WO2014159244A2 (en) | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | O-GlcNAc TAU ANTIBODY AND USE THEREOF |
US9688747B2 (en) | 2013-03-15 | 2017-06-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
BR112015023262B8 (pt) | 2013-03-15 | 2024-02-06 | Ac Immune Sa | Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo |
TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
-
2015
- 2015-06-25 TW TW108111964A patent/TWI734975B/zh active
- 2015-06-25 TW TW104120634A patent/TWI664190B/zh not_active IP Right Cessation
- 2015-06-25 TW TW109146224A patent/TW202136296A/zh unknown
- 2015-06-26 MY MYPI2016704772A patent/MY184540A/en unknown
- 2015-06-26 CN CN201580046263.9A patent/CN106659759B/zh active Active
- 2015-06-26 MA MA040229A patent/MA40229A/fr unknown
- 2015-06-26 NZ NZ727919A patent/NZ727919A/en not_active IP Right Cessation
- 2015-06-26 SG SG10201914067XA patent/SG10201914067XA/en unknown
- 2015-06-26 PE PE2016002780A patent/PE20170665A1/es unknown
- 2015-06-26 ES ES15810923T patent/ES2959528T3/es active Active
- 2015-06-26 KR KR1020167036625A patent/KR102431596B1/ko active IP Right Grant
- 2015-06-26 CA CA2953809A patent/CA2953809C/en active Active
- 2015-06-26 CR CR20170026A patent/CR20170026A/es unknown
- 2015-06-26 WO PCT/US2015/038002 patent/WO2015200806A2/en active Application Filing
- 2015-06-26 MX MX2017000205A patent/MX2017000205A/es unknown
- 2015-06-26 RU RU2017102514A patent/RU2743152C2/ru active
- 2015-06-26 EP EP15810923.1A patent/EP3182987B1/en active Active
- 2015-06-26 BR BR112016030686A patent/BR112016030686A2/pt not_active Application Discontinuation
- 2015-06-26 UA UAA201700707A patent/UA122771C2/uk unknown
- 2015-06-26 SG SG11201610862VA patent/SG11201610862VA/en unknown
- 2015-06-26 CA CA3094638A patent/CA3094638A1/en not_active Abandoned
- 2015-06-26 UY UY0001036194A patent/UY36194A/es not_active Application Discontinuation
- 2015-06-26 AU AU2015279643A patent/AU2015279643B2/en active Active
- 2015-06-26 JP JP2017520755A patent/JP6626892B2/ja active Active
-
2016
- 2016-09-06 US US15/257,086 patent/US9957317B2/en active Active
- 2016-12-22 IL IL249734A patent/IL249734B/en active IP Right Grant
- 2016-12-22 ZA ZA2016/08875A patent/ZA201608875B/en unknown
- 2016-12-23 PH PH12016502608A patent/PH12016502608A1/en unknown
- 2016-12-26 DO DO2016000335A patent/DOP2016000335A/es unknown
- 2016-12-27 CL CL2016003346A patent/CL2016003346A1/es unknown
-
2017
- 2017-01-04 MX MX2021008888A patent/MX2021008888A/es unknown
- 2017-01-27 EC ECIEPI20175649A patent/ECSP17005649A/es unknown
-
2018
- 2018-03-23 US US15/934,413 patent/US20180371066A1/en not_active Abandoned
-
2019
- 2019-12-02 JP JP2019217837A patent/JP2020054356A/ja active Pending
-
2020
- 2020-03-27 IL IL273656A patent/IL273656B/en unknown
-
2021
- 2021-01-04 PH PH12021550023A patent/PH12021550023A1/en unknown
- 2021-07-08 AU AU2021204800A patent/AU2021204800A1/en active Pending
- 2021-12-02 JP JP2021195942A patent/JP2022050392A/ja active Pending
- 2021-12-02 IL IL288649A patent/IL288649A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016030686A2 (pt) | anticorpos anti tau humanizados | |
CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
BR112016026197A2 (pt) | anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de câncer de pulmão de não pequenas células | |
BR112017006468A2 (pt) | anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer | |
BR112017003194B8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
PE20190737A1 (es) | Anticuerpos anti-cd27 | |
SV2017005380A (es) | Tratamientos conjuntos con anticuerpos anti cd40 | |
BR112016005303A2 (pt) | anticorpos anti-b7-h1 para tratamento de tumores | |
BR112016027912A2 (pt) | molécula de ligação triespecífica capaz de se ligar de maneira imunoespecífica a três epítopos diferentes, composição farmacêutica, método de tratamento de câncer, método de tratamento de uma doença associada à presença de um patógeno, anticorpo anti-ror1, ou fragmento de ligação a ror1, fragmento de anticorpo biespecífico, bite ou anticorpo de cadeia simples, e método de tratamento de câncer | |
BR112017027549A2 (pt) | anticorpo para cd40 | |
BR112017005517A2 (pt) | anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes | |
AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
BR112017023646A2 (pt) | proteínas agonistas de receptor de cd40 de cadeia simples | |
BR112016016207A2 (pt) | Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos | |
BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
EA201692539A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
BR112018075434A2 (pt) | anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor. | |
EA201790475A1 (ru) | Способы лечения системной красной волчанки с использованием доменного антитела против cd28 | |
BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
BR112017007877A2 (pt) | anticorpo ou fragmento do mesmo, epítopo em ccr6 humana solúvel, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição e imunoconjugado | |
EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
EA202191666A1 (ru) | Антитела к il-27 и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |